Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin.[1]
- ^ Hutchinson, Michael (2007). "Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268. doi:10.2147/tcrm.2007.3.2.259. ISSN 1176-6336.
{{cite journal}}: CS1 maint: unflagged free DOI (link)